Form 4: Boston Scientific EVP Wendy Carruthers Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Boston Scientific's Executive Vice President of Human Resources, Wendy Carruthers, exercised stock options and sold shares of common stock under a pre-established 10b5-1 trading plan.
Summary
- Wendy Carruthers, Executive Vice President of Human Resources at Boston Scientific, executed transactions involving the company's stock on December 2, 2024.
- These transactions included the exercise of stock options to acquire 3,066 shares at $17.26 and 1,197 shares at $24.55.
- Following the option exercises, Ms. Carruthers sold 6,983 shares of common stock at $90.78.
- The transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.
- After these transactions, Ms. Carruthers directly owns 29,308 shares of common stock and 13,183 stock options.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It does not indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock transactions and avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the medical device industry like Medtronic (MDT) and Abbott (ABT).
- The reported transactions are typical for executives who receive stock options as part of their compensation packages.
- The prices at which the options were exercised and the shares were sold are consistent with market prices at the time of the transactions.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.
Key Dates
| Date | Description |
|---|---|
| 11/17/2023 | Date the Rule 10b5-1 trading plan was adopted. |
| 12/02/2024 | Date of the stock option exercises and stock sale. |
| 12/03/2024 | Date the Form 4 was signed. |
| 02/22/2026 | Expiration date of the first stock option grant. |
| 02/28/2027 | Expiration date of the second stock option grant. |
Keywords
insider trading, stock options, Rule 10b5-1, executive compensation, stock sale, Boston Scientific, BSX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.